A 52‐week pilot study of the effects of exenatide on body weight in patients with hypothalamic obesity
Year: 2016
Type: article
Study design: Clinical Trial
Abstract: OBJECTIVE: Hypothalamic obesity (HO) is a common complication of hypothalamic tumors, and effective therapies are lacking. The objective of this pilot study was to investigate changes in body weight before and during treatment with exenatide. METHODS: This was a prospective, open-label, 52-week pilot study of exenatide (10 mcg b.i.d.) in adults with HO. Ten patients enrolled, and eight completed the study. Study measures included indirect calorimetry, body composition, buffet meals, diet recall, actigraphy, and hormone assays. RESULTS: Participants had obesity with a baseline weight of 137.2 ± 37.6 kg. Exenatide therapy was well tolerated. Change in weight with exenatide therapy was not significant (-1.4 ± 4.3 kg [95% CI -4.9 to 2.2], P = 0.40), but six out of eight completers lost weight (-6.2 to -0.2 kg). Participants reported significantly lower intake on food recall during treatment compared with baseline (7837.8 ± 2796.6 vs. 6258.4 ± 1970.7 kJ [95% CI -2915.8 to -242.6], P = 0.027), but there was no change in intake during buffet meals. CONCLUSIONS: Significant weight loss was not observed in patients with HO treated with exenatide, but 75% of completers had stable or decreasing weight. Further studies are needed to evaluate weight loss efficacy in patients with HO.
Source: Obesity
DOI: 10.1002/oby.21493
Institution: Vanderbilt University
Language: English
Subfield: Endocrine and Autonomic Systems
Field: Neuroscience
Domain: Life Sciences
Open Access status: bronze
Funders: AstraZeneca, Vanderbilt University, Vanderbilt University Medical Center, Georgia Clinical and Translational Science Alliance, Zafgen, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G117257630, G1221739687, Early Onset Obesity and Cognitive Impairment in Pseudohypoparathyroidism, The Vanderbilt Institute for Clinical and Translational Research (VICTR), Vanderbilt Mouse Metabolic Phenotyping Center, G4424950377, G5436572433, Diabetes Research and Training Center, Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Center at Vanderbilt University, The Vanderbilt Institute for Clinical and Translational Research (VICTR), G9000052735, Molecular and Cellular Basis for Digestive Diseases, Vanderbilt Diabetes Research Center
OpenAlex ID: W2345484103
